ISSN 2307-8960 (online)

World Journal of *Clinical Cases*

World J Clin Cases 2023 August 16; 11(23): 5416-5627

Published by Baishideng Publishing Group Inc

World Journal of Clinical Cases

Contents

Thrice Monthly Volume 11 Number 23 August 16, 2023

REVIEW

ORIGINAL ARTICLE

Retrospective Cohort Study

Retrospective Study

Observational Study

Prospective Study

SYSTEMATIC REVIEWS

World Journal of Clinical Cases

Thrice Monthly Volume 11 Number 23 August 16, 2023

Contents

World Journal of Clinical Cases

Thrice Monthly Volume 11 Number 23 August 16, 2023

Contents

World Journal of Clinical Cases

Thrice Monthly Volume 11 Number 23 August 16, 2023

Contents

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Ellis J Neufeld, MD, PhD, Chief Physician, Executive Vice President, Professor, Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, United States. ellis.neufeld@stjude.org

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (*WJCC*, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJCC* as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

PUBLICATION DATE
August 16, 2023

World Journal of Clinical Cases

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2023 August 16; 11(23): 5468-5478

DOI: 10.12998/wjcc.v11.i23.5468

ISSN 2307-8960 (online)

ORIGINAL ARTICLE

Observational Study

Effect of vitamin supplementation on polycystic ovary syndrome and key pathways implicated in its development: A Mendelian randomization study

Jia-Yan Shen, Li Xu, Yang Ding, Xiao-Yun Wu

Specialty type: Reproductive biology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Rahmoune H, Algeria

Received: March 29, 2023
Peer-review started: March 29, 2023
First decision: July 3, 2023
Revised: July 7, 2023
Accepted: July 17, 2023
Article in press: July 17, 2023
Published online: August 16, 2023

Jia-Yan Shen, Xiao-Yun Wu, Department of Reproductive Medicine, Huzhou Maternity & Child Health Care Hospital, Huzhou 313000, Zhejiang Province, China

Li Xu, Department of Obstetrics and Gynecology, Huzhou Maternity & Child Health Care Hospital, Huzhou 313000, Zhejiang Province, China

Yang Ding, Department of Dermatology, Zhejiang Provincial People's Hospital, Hangzhou 310014, Zhejiang Province, China

Corresponding author: Xiao-Yun Wu, MD, Doctor, Department of Reproductive Medicine, Huzhou Maternity & Child Health Care Hospital, No. 2 East Street, Wuxing District, Huzhou 313000, Zhejiang Province, China. wxy2103859@163.com

Abstract

BACKGROUND

Many epidemiologic investigations have explored the relationship between viatmins and polycystic ovary syndrome (PCOS). However, the effectiveness of vitamin, vitamin-like nutrient, or mineral supplementation in reducing the risk of PCOS remains a subject of debate.

AIM

To investigate the impact of plasma levels of vitamins A, B12, D, E, and K on PCOS and key pathways implicated in its development, namely, insulin resistance, hyperlipidemia, and obesity, through Mendelian randomization (MR) analysis.

METHODS

Single nucleotide polymorphisms associated with vitamin levels were selected from genome-wide association studies. The primary analysis was performed using the random-effects inverse-variance-weighted approach. Complementary analyses were conducted using the weighted median, MR-Egger, MR-robust adjusted profile score, and MR-PRESSO approaches.

RESULTS

The results provided suggestive evidence of a decreased risk of PCOS with genetically predicted higher levels of vitamin E (odds ratio [OR] = 0.118; 95%

confidence interval [CI]: 0.071–0.226; $P < 0.001$) and vitamin B12 (OR = 0.753, 95%CI: 0.568–0.998, $P = 0.048$). An association was observed between vitamin E levels and insulin resistance (OR = 0.977, 95%CI: 0.976–0.978, $P < 0.001$). Additionally, genetically predicted higher concentrations of vitamins E, D, and A were suggested to be associated with a decreased risk of hyperlipidemia. Increased vitamins K and B12 levels were linked to a lower obesity risk (OR = 0.917, 95%CI: 0.848–0.992, $P = 0.031$).

CONCLUSION

The findings of this MR study suggest a causal relationship between increased vitamins A, D, E, K, and B12 levels and a reduced risk of PCOS or primary pathways implicated in its development.

Key Words: Vitamin levels; Polycystic ovary syndrome; Key pathways; Mendelian randomization; Casual effect

Core Tip: Higher vitamins A, D, E, K, and B12 levels were casually related to a reduced risk of polycystic ovary syndrome (PCOS) or main pathways implicated in its development, as suggested by our Mendelian randomization investigation. More prospective and functional *in vivo* and *in vitro* trials are required to clarify the role of vitamin supplements in the onset of PCOS and main pathways implicated in its development.

Citation: Shen JY, Xu L, Ding Y, Wu XY. Effect of vitamin supplementation on polycystic ovary syndrome and key pathways implicated in its development: A Mendelian randomization study. *World J Clin Cases* 2023; 11(23): 5468-5478
URL: https://www.wjgnet.com/2307-8960/full/v11/i23/5468.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i23.5468

INTRODUCTION

Polycystic ovary syndrome (PCOS) is a widespread endocrine disease that affects a large number of sexually mature women globally[1,2]. The prevalence of PCOS according to the diagnostic criteria ranges from 6% to 10%[3]. Patients with PCOS are at an increased risk of diabetes mellitus, atherogenic dyslipidemia, systemic inflammation, hypertension, and coagulation disorders[4,5].

PCOS arises from a combination of hereditary and epigenetic vulnerability, insulin resistance, and adiposity-related mechanisms[6,7]. Modifying one's lifestyle is among the recommended options for PCOS treatment and is highly advised for women seeking to improve their quality of life[8]. In recent years, there has been growing interest in nutritional supplements[9,10]. However, the potential of vitamin, vitamin-like nutrient, or mineral supplementation to reduce the risk of PCOS remains debatable. A meta-analysis found no evidence that vitamin D supplementation improved or alleviated metabolic and hormonal dysregulations in PCOS[11]. Nevertheless, convincing conclusions cannot be drawn at this point, and vitamin K may be a viable option for alleviating oxidative stress and improving glycemic control in PCOS [12].

The supplementation of specific nutrients and complementary treatments may improve the health conditions of women with PCOS by modulating critical pathways implicated in PCOS development, such as insulin signaling, insulin resistance, and lipid metabolism. However, observational studies largely constitute the primary evidence regarding the correlation between vitamin supplements and PCOS, which can be influenced by confounding or reverse causation. Mendelian randomization (MR) has emerged as an effective technique to identify the causal relationship of risk factors with diseases by using genetic variants as instrumental variables (IVs)[13]. MR enables stronger causal inferences than typical observational studies due to the random assignment of genetic variations during conception between parents and offspring.

To date, no MR analysis has explored the causal effect of vitamin supplements on PCOS. In this study, we aimed to conduct a two-sample MR analysis to assess the impact of plasma levels of vitamins A, B12, D, E, and K on PCOS and key pathways implicated in its development, namely, insulin resistance, hyperlipidemia, and obesity.

MATERIALS AND METHODS

Study design

Vitamin supplementation has the potential to improve health outcomes in women with PCOS by influencing crucial pathways such as insulin resistance, lipid metabolism, and obesity. We conducted a two-sample MR analysis to identify the effect of plasma levels of vitamins A, B12, D, E, and K on PCOS and its associated pathways, including insulin resistance, hyperlipidemia, and obesity. Figure 1 provides a detailed overview of the study design.



DOI: 10.12998/wjcc.v11.i23.5468

Figure 1 Summary of the Mendelian randomization investigation. Genetic variations associated with plasma vitamin levels were used as instrumental variables to examine the correlation between exposures and outcomes.

Study participants

The genetic association data for vitamin D were analyzed using blood samples obtained twice from the United Kingdom Biobank, a major population cohort[14] comprising volunteers aged 37-73 years from 22 evaluation centers across the United Kingdom, aiming to enhance disease prevention[15]. Genetic association data for vitamin B12 were obtained from sequencing initiatives in Iceland and Denmark involving European populations, explaining 5.1% of the variation in circulating vitamin B12 levels[16]. Genetic instruments for vitamins A and E concentration were obtained from three cohorts: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study; and the Nurses' Health Study[17]. Data for vitamin K were obtained from the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium Nutrition Working Group, which involved 2138 individuals. Genetic correlations were examined using linear models adjusted for key components, sex, age, and study-specific factors[18]. To mitigate potential bias stemming from ancestry, participation was limited to individuals of European heritage. All analyses of this study were based on publicly accessible databases; thus, no additional ethical approval or informed consent was required. The genome-wide association studies (GWAS) included in the analysis are presented in Table 1.

Outcome data source

The primary measure in this MR study was PCOS. Table 1 provides a summary of the specific sources of outcome data. Summary statistics for PCOS in individuals of European ancestry were obtained from the FinnGen Biobank consortium, which includes 118870 participants. The FinnGen project is a unique research endeavor that integrates genetic data with digital healthcare information from over 500000 Finnish biobank participants[19]. Hyperlipidemia, obesity, and insulin resistance are key pathways related to PCOS. Hyperlipidemia and obesity data were also sourced from the FinnGen Biobank consortium. Insulin resistance data were retrieved from the Meta-Analyses of Glucose and Insulin-related traits Consortium, involving up to 37037 participants[20].

Genetic instruments for vitamin concentration

Single nucleotide polymorphisms (SNPs) associated with vitamins D, E, A, and B12 were defined at the genome-wide significance threshold ($P < 5 \times 10^{-8}$). Owing to the limited number of SNPs for vitamin K, SNPs at a level of genome-wide significance of $P < 5 \times 10^{-6}$ were chosen as IVs. To ensure instrument validity, SNPs were filtered within a 1000 kb window with an $r^2 < 0.01$ threshold[21]. Through a search of the *GWAS* Catalog (https://www.ebi.ac.uk/gwas/), we identified pleiotropic IV SNPs associated with any confounding factor related to the outcome. Estimates of the effects of these vitamin-related genetic variations on outcome datasets were collected. Additionally, SNP harmonization was conducted to restore allele orientation. The final selection of SNPs used in this MR is presented in Supplementary Tables 1-20.

SNP-based Mendelian randomization estimates

The primary analyses were performed using the random-effects inverse-variance-weighted (IVW) approach, assuming all SNPs as valid IVs. The IVW method is considered highly reliable when there is no evidence of directional pleiotropy among the selected IVs (P value for MR-Egger intercept > 0.05)[22]. Complementary analyses were conducted using the weighted median[23] and MR-Egger[23] methods as supplements to the IVW approach. The weighted median model generates consistent causal findings when over 50% of the weights are derived from valid SNPs. The MR-Egger regression method can detect and adjust for directional pleiotropy[24].

Table 1 Details of the genome-wide association studies included in this Mendelian randomization analysis

Exposures/Outcomes	Consortium	Ethnicity	Participants	Number of SNPs
Vitamin D	United Kingdom Biobank	European	496946	6896093
Vitamin K	CHAGRE	European	2138	/
Vitamin E	ATBC&PLCO&NHS	European	7781	/
Vitamin A	ATBC&PLCO&NHS	European	7778	/
Vitamin B12	SIID	European	45576	/
Polycystic ovarian syndrome	FinnGen Biobank	European	118870	16379676
Hyperlipidaemia	FinnGen Biobank	European	201497	16380389
Obesity	FinnGen Biobank	European	218735	16380465
Insulin resistance	MAGIC	European	37037	2435028

SNPs: Single nucleotide polymorphisms.

Furthermore, we performed MR-robust adjusted profile score (MR-RAPS) using the "Huber" loss function to model a random-effects distribution of the pleiotropic effects of genetic variants[25]. Additionally, the MR-PRESSO approach was used to identify outlier SNPs and provide causal estimations after removing probable outliers, assuming that the employed SNPs are valid[26].

Heterogeneity and pleiotropy analysis

We used Cochran's Q test to analyze the heterogeneity of the estimations from each SNP. When there was no statistically significant heterogeneity ($P > 0.05$), we used the fixed-effects model; however, the random-effects model was used to produce highly conservative estimations. Pleiotropy analysis was conducted using the MR-Egger intercept test. A zero intercept for MR-Egger ($P > 0.05$) indicates no presence of pleiotropic bias[27].

All tests were performed using the statistical program "R" v3.5 with the "TwoSampleMR," "MR-PRESSO," "Mr.raps," and "Forestplot" packages. All analyses were two-sided, and statistical significance was set at $P < 0.05$.

RESULTS

Association of vitamin E supplementation with PCOS and key pathways implicated in its development

In the fixed-effects IVW estimations, genetically projected higher values of vitamin E were associated with a reduced risk of PCOS (Figure 2 and Supplementary Table 21). For 1-SD increase in genetically projected vitamin E concentrations, the combined odds ratio (OR) was 0.118 (95% confidence interval [CI]: 0.071–0.226, $P < 0.001$). The association remained consistent in complementary analyses when using the random-effects IVW and weighted median techniques. Higher vitamin E levels were correlated with a decreased risk of hyperlipidemia (OR = 0.259, 95%CI: 0.111–0.608, $P = 0.002$) and insulin resistance (OR = 0.977, 95%CI: 0.976–0.978, $P < 0.001$). However, no impact of vitamin E on obesity was observed *via* the fixed-effects IVW approach.

Association of vitamin D supplementation with PCOS and key pathways implicated in its development

Genetically anticipated higher vitamin D concentrations were suggestive of a decreased risk of hyperlipidemia, as indicated *via* the random-effects IVW approach (OR = 0.749, 95%CI: 0.592–0.948, $P = 0.016$; Figure 3 and Supplementary Table 21). The results remained consistent in the fixed-effects IVW approach (OR = 0.749, 95%CI: 0.647–0.868, $P = 0.001$). However, other complementary analyses yielded negative results. Additionally, all MR methods did not support a link between genetically projected vitamin D concentrations and PCOS, obesity, and insulin resistance.

No evidence of directional pleiotropy was observed, but heterogeneity was present for vitamin D analysis on the key pathways of PCOS (Table 2). Furthermore, outlier SNPs were identified using the MR-PRESSO test, and the causal effect estimates of vitamin E on the risk of PCOS and key pathways implicated in its development were not statistically significant (Table 3).

Association of vitamin K supplementation with PCOS and key pathways implicated in its development

Figure 4A presents the MR estimation for the association of vitamin E supplementation with PCOS and key pathways implicated in its development. According to the fixed-effects IVW method, increased vitamin E levels were associated with a reduced risk of obesity (OR = 0.917, 95%CI: 0.848–0.992, $P = 0.031$; Figure 4A and Supplementary Table 21). However, no causal effect of vitamin E on PCOS, hyperlipidemia, and insulin resistance was observed. No evidence was observed of horizontal pleiotropy (P value for intercept > 0.05; Table 2) or heterogeneity as measured using Cochran's Q test (P value for Cochran's $Q > 0.05$; Table 3).

Table 2 Heterogeneity and pleiotropy tests of the Mendelian randomization analysis

Exposure/Outcome	Heterogeneity		Pleiotropy	
	Cochran's Q	*P* value	Egger-intercept	*P* value
Vitamin D/PCOS	180.692	0.368	-0.006	0.487
Vitamin D/Hyperlipidaemia	449.648	< 0.001	-0.004	0.425
Vitamin D/Obesity	402.633	< 0.001	0.002	0.494
Vitamin D/Insulin resistance	169.312	0.001	-0.002	0.059
Vitamin K/PCOS	2.926	0.570	0.029	0.752
Vitamin K/Hyperlipidaemia	5.151	0.272	0.044	0.290
Vitamin K/Obesity	7.086	0.131	0.049	0.150
Vitamin K/Insulin resistance	7.932	0.094	-0.008	0.469
Vitamin B12/PCOS	1.284	0.973	0.004	0.930
Vitamin B12/Hyperlipidaemia	3.346	0.764	-0.022	0.297
Vitamin B12/Obesity	5.046	0.540	0.003	0.858
Vitamin B12/Insulin resistance	3.578	0.466	-0.003	0.451

PCOS: Polycystic ovary syndrome.

Table 3 Mendelian randomization PRESSO estimates for effect of vitamin supplements on risk of polycystic ovary syndrome and its risk factors

Exposure trait	Outcome trait	*N*	Beta	*P* value
Vitamin D	PCOS	172	-0.092	0.645
Vitamin D	Hyperlipidaemia	169	-0.141	0.126
Vitamin D	Obesity	174	-0.031	0.618
Vitamin D	Insulin resistance	117	-0.005	0.789
Vitamin B12	PCOS	6	-0.284	0.005
Vitamin B12	Hyperlipidaemia	6	-0.103	0.063
Vitamin B12	Obesity	6	-0.088	0.048
Vitamin B12	Insulin resistance	6	-0.015	0.319

PCOS: Polycystic ovary syndrome.

Association of vitamin B12 supplementation with PCOS and key pathways implicated in its development

The fixed-effects IVW estimations suggested a link between genetically anticipated higher vitamin B12 Levels and a lower risk of PCOS (OR = 0.753, 95%CI: 0.568–0.998, $P = 0.048$) and obesity (OR = 0.917, 95%CI: 0.843–0.995, $P = 0.037$; Figure 4B and Supplementary Table 21). However, no correlation was observed between vitamin B12 levels and hyperlipidemia or insulin resistance.

No evidence of horizontal pleiotropy (P value for intercept > 0.05; Table 2) or heterogeneity as indicated by the Cochran's Q test (P value for Cochran's Q > 0.05; Table 3) was found. After correcting for the outline SNPs, the causal effect estimates of vitamin B12 on the risk of PCOS ($P = 0.005$) and obesity ($P = 0.048$) remained statistically significant (Table 3).

Association of vitamin A supplementation with PCOS and key pathways implicated in its development

The IVW estimate showed a significant association between genetically predicted vitamin A levels and hyperlipidemia risk (OR = 0.287, 95%CI: 0.258–0.320, $P < 0.001$; Figure 4C and Supplementary Table 21). This association was consistent with complementary analyses using the random-effects IVW method. However, no statistically significant causal effect estimates of vitamin A on the risk of PCOS, obesity, and insulin resistance were observed.



DOI: 10.12998/wjcc.v11.i23.5468

Figure 2 Association of vitamin E supplementation with polycystic ovary syndrome, hyperlipidemia, obesity, and insulin resistance. IVW (re): Inverse variance weighted with random effect; IVW(fe): Inverse variance weighted with fixed effect; VE: Vitamin E; OR: Odds ratio; PCOS: Polycystic ovary syndrome.



DOI: 10.12998/wjcc.v11.i23.5468

Figure 3 Association of vitamin D supplementation with polycystic ovary syndrome, hyperlipidemia, obesity, and insulin resistance. MR-RAPS: MR-robust adjusted profile score; OR: Odds ratio; PCOS: Polycystic ovary syndrome; VD: Vitamin D.

DISCUSSION

Supplementation with individual nutrients may improve health outcomes in women with PCOS by altering crucial PCOS-related pathways, such as insulin signaling, insulin resistance, and lipid metabolism. This MR analysis, based on large-scale genetic consortia, provides suggestive evidence supporting a causal effect of higher vitamins E and B12 levels on a decreased risk of PCOS. Our findings indicated that genetically predicted levels of vitamins K and B12 were related to a lower risk of obesity. Additionally, genetically predicted higher levels of vitamins E, D, and A were suggestively



DOI: 10.12998/wjcc.v11.i23.5468

Figure 4 Association of vitamin supplementation with polycystic ovary syndrome, hyperlipidemia, obesity, and insulin resistance. A: Vitamin K; B: Vitamin B12; C: Vitamin A. OR: Odds ratio; PCOS: Polycystic ovary syndrome.

associated with a decreased risk of hyperlipidemia, while higher vitamin E levels were suggestively linked to a lower risk of insulin resistance.

Previous studies have employed cross-sectional, case-control, and cohort designs to investigate the association between vitamin supplementation and the risk of PCOS. However, the findings remain disputed. For instance, Panidis *et al*[28] found that patients with PCOS had lower levels of vitamin D compared with controls. Hahn *et al*[29] demonstrated a link between low serum 25-hydroxyvitamin D values and insulin resistance and obesity in women with PCOS. However, a meta-analysis of 30 trials did not provide evidence that vitamin D supplementation reduces or alleviates metabolic and hormonal dysregulations in PCOS[11]. This discrepancy may be attributed to the limitations of observational investigations, which are prone to residual confounding and imprecise measurements of confounders. In contrast, MR analysis offers highly accurate causal conclusions by leveraging the random assignment of genetic variations from parents to children.

A recent systemic review of 12 articles indicated that vitamin E supplementation improves lipid profile, reduces insulin levels, and decreases HOMA-IR values[30,31]. This is consistent with our findings suggesting that increased vitamin E concentrations are associated with a decreased risk of PCOS, hyperlipidemia, and insulin resistance. The anti-oxidative property of vitamin E, along with its effects on oxidative stress metrics, may explain its positive effects on lipid profile enhancement and insulin resistance[30]. Vitamin E acts as a substantial fat antioxidant, neutralizing peroxyl radicals and preventing the oxidation of polyunsaturated fatty acids[32,33]. Coenzyme Q10 is often supplemented together with vitamin E due to its synergistic roles in sustaining mitochondrial activity and integrity[10]. Foreign studies have shown favorable effects of coenzyme Q10 and vitamin E supplementation on blood insulin, HOMA-IR, and total testosterone levels in women with PCOS[34,35].

The role of vitamin B12 on PCOS remains unclear. B-group vitamins are responsible for breaking down Hcy in the blood, which is associated with insulin resistance[36]. However, our study provides no evidence of a causal effect of vitamin B12 on insulin resistance. A randomized controlled trial with B-group vitamin supplementation indicated a reduction in Hcy concentrations but no changes in insulin resistance[37].

Lipid metabolism is a key pathway in PCOS. Our MR analysis revealed that genetically predicted higher levels of vitamins E, D, and A are suggestively associated with a decreased risk of hyperlipidemia. This finding suggests the potential benefits of supplementing these vitamins. However, further functional studies *in vivo* are necessary to explore the underlying mechanisms. Additionally, adipose tissue plays a role as a metabolic and endocrine organ, and its overabundance can lead to alterations in body homeostasis and vitamin deficiency[2,38]. Therefore, vitamin supplementation may be beneficial in improving health outcomes in women with PCOS and obesity.

This study is the first MR investigation exploring the association between vitamin supplementation and PCOS and key pathways implicated in its development. The MR design strengthens causal inference by reducing residual confounding and other biases[39]. The use of data obtained from independent large GWAS ensures the reliability of the results. Furthermore, to address the potential influence of pleiotropic SNPs on our data, we implemented various techniques such as weighted median and MR-RAPS to minimize violations of the MR assumptions. Additionally, we used MR-PRESSO to identify and assess the probable presence of pleiotropy among the SNPs. Lastly, the genetic variants used as IVs were located on different chromosomes, minimizing the potential gene-gene interactions in our findings.

Nevertheless, our study has some limitations. First, the vitamin levels analyzed were genetically predicted concentrations, approximating average effects over the life course. The concentration of vitamins is influenced by the diet. Second, the analysis was restricted to participants of European ancestry to minimize bias due to population stratification; this limits the generalizability of the findings to non-European populations. Third, weak instrument bias may be present, given the low variability of vitamin levels explained by the SNPs. Fourth, although our study incorporated data from extensive genetic epidemiology networks, it may not be adequately powered to detect considerably small effects. Fifth, we were unable to obtain data stratified by the PCOS phenotype, warranting further investigation into the effect of vitamin supplements on different PCOS phenotypes. Lastly, we were unable to assess linear associations between vitamin levels and PCOS. Further prospective and functional studies are warranted to elucidate the role of vitamin supplements in PCOS.

CONCLUSION

Our MR analysis suggests that higher levels of vitamins A, D, E, K, and B12 are causally related to a reduced risk of PCOS or key pathways implicated in its development. Further prospective population-based studies and *in vivo* and *in vitro* trials are required to clarify the precise role of vitamin supplements in the onset of PCOS and key pathways implicated in its development.

ARTICLE HIGHLIGHTS

Research background

Outcomes from conventional observational investigations are often based on the limited sample size and influenced by confounding factors.

Research motivation

To conduct a two-sample mendelian randomization (MR) analysis to assess the impact of plasma levels of vitamins A, B12, D, E, and K on polycystic ovary syndrome (PCOS) and key pathways implicated in its development, namely, insulin resistance, hyperlipidemia, and obesity.

Research objectives

To explore the causal relationship between increased vitamins A, D, E, K, and B12 values and a reduced risk of PCOS or primary pathways implicated in its development.

Research methods

The inverse variance weighted (IVW) method is considered highly reliable when there is no evidence of directional pleiotropy among the selected instrumental variables. Complementary analyses were conducted using the weighted median and MR-Egger methods as supplements to the IVW method. Furthermore, the MR-robust adjusted profile score (MR-RAPS) and MR-PRESSO approaches were used to identify outlier single nucleotide polymorphisms (SNPs) and provide causal estimations after removing probable outliers, assuming that the employed SNPs are valid.

Research results

This MR analysis, based on large-scale genetic consortia, provided suggestive evidence supporting a causal effect of higher vitamins E and B12 levels on a decreased risk of PCOS. Our findings indicated that genetically predicted levels of vitamins K and B12 were related to a lower risk of obesity. Additionally, genetically predicted higher levels of vitamins E, D, and A were suggestively associated with a decreased risk of hyperlipidemia, while higher vitamin E levels were suggestively linked to a lower risk of insulin resistance.

Research conclusions

Higher levels of vitamins A, D, E, K, and B12 are causally related to a reduced risk of PCOS or key pathways implicated in its development.

Research perspectives

Further prospective population-based studies and *in vivo* and *in vitro* trials are required to clarify the precise role of vitamin supplements in the onset of PCOS and key pathways implicated in its development.

FOOTNOTES

Author contributions: Shen JY, Xu L, Ding Y, and Wu XY designed the research study; Shen JY and Xu L performed the research; Shen JY and Ding Y contributed new reagents and analytic tools; Shen JY and Wu XY analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.

Supported by the Huzhou Science and Technology Plan, No. 2022GY27.

Institutional review board statement: No institutional review board statement is required since this study was based on public databases.

Informed consent statement: The data was from large sample size GWAS, and no informed consent statement is required.

Conflict-of-interest statement: All authors declare that they have no conflicts of interest to disclose.

Data sharing statement: The data can be accessed from the following website: https://gwas.mrcieu.ac.uk/. Additionally, we have presented the relevant data in Supplementary Tables 1–20.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Country/Territory of origin: China

ORCID number: Xiao-Yun Wu 0009-0001-0010-4286.

S-Editor: Liu JH
L-Editor: Wang TQ
P-Editor: Cai YX

REFERENCES

1 **Sadeghi HM**, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, Nikfar S, Tsatsakis A, Abdollahi M. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. *Int J Mol Sci* 2022; **23** [PMID: 35054768 DOI: 10.3390/ijms23020583]

2 **Shrivastava S**, Conigliaro RL. Polycystic Ovarian Syndrome. *Med Clin North Am* 2023; **107**: 227-234 [PMID: 36759093 DOI: 10.1016/j.mcna.2022.10.004]

3 **Bozdag G**, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod* 2016; **31**: 2841-2855 [PMID: 27664216 DOI: 10.1093/humrep/dew218]

4 **Anagnostis P**, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. *Metabolism* 2018; **86**: 33-43 [PMID: 29024702 DOI: 10.1016/j.metabol.2017.09.016]

5 **Ibáñez L**, de Zegher F. Adolescent PCOS: a postpubertal central obesity syndrome. *Trends Mol Med* 2023; **29**: 354-363 [PMID: 36964058 DOI: 10.1016/j.molmed.2023.02.006]

6 **Joham AE**, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, Boyle J, Teede HJ. Polycystic ovary syndrome. *Lancet Diabetes Endocrinol* 2022; **10**: 668-680 [PMID: 35934017 DOI: 10.1016/S2213-8587(22)00163-2]

7 **Zeng X**, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. *Clin Chim Acta* 2020; **502**: 214-221 [PMID: 31733195 DOI: 10.1016/j.cca.2019.11.003]

8 **Teede HJ**, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Erratum. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod* 2019; **34**: 388 [PMID: 30521039 DOI: 10.1093/humrep/dey363]

9 **Menichini D**, Ughetti C, Monari F, Di Vinci PL, Neri I, Facchinetti F. Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature. *Gynecol Endocrinol* 2022; **38**: 623-631 [PMID: 35713558 DOI: 10.1080/09513590.2022.2089106]

10 **Heidari H**, Hajhashemy Z, Saneei P. A meta-analysis of effects of vitamin E supplementation alone and in combination with omega-3 or magnesium on polycystic ovary syndrome. *Sci Rep* 2022; **12**: 19927 [PMID: 36402830 DOI: 10.1038/s41598-022-24467-0]

11 **He C**, Lin Z, Robb SW, Ezeamama AE. Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis. *Nutrients* 2015; **7**: 4555-4577 [PMID: 26061015 DOI: 10.3390/nu7064555]

12 **Alesi S**, Ee C, Moran LJ, Rao V, Mousa A. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. *Adv Nutr* 2022; **13**: 1243-1266 [PMID: 34970669 DOI: 10.1093/advances/nmab141]

13 **Emdin CA**, Khera AV, Kathiresan S. Mendelian Randomization. *JAMA* 2017; **318**: 1925-1926 [PMID: 29164242 DOI: 10.1001/jama.2017.17219]

14 **Revez JA**, Lin T, Qiao Z, Xue A, Holtz Y, Zhu Z, Zeng J, Wang H, Sidorenko J, Kemper KE, Vinkhuyzen AAE, Frater J, Eyles D, Burne THJ, Mitchell B, Martin NG, Zhu G, Visscher PM, Yang J, Wray NR, McGrath JJ. Genome-wide association study identifies 143 loci associated with 25 hydroxyvitamin D concentration. *Nat Commun* 2020; **11**: 1647 [PMID: 32242144 DOI: 10.1038/s41467-020-15421-7]

15 **Sudlow C**, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; **12**: e1001779 [PMID: 25826379 DOI: 10.1371/journal.pmed.1001779]

16 **Grarup N**, Sulem P, Sandholt CH, Thorleifsson G, Ahluwalia TS, Steinthorsdottir V, Bjarnason H, Gudbjartsson DF, Magnusson OT, Sparsø T, Albrechtsen A, Kong A, Masson G, Tian G, Cao H, Nie C, Kristiansen K, Husemoen LL, Thuesen B, Li Y, Nielsen R, Linneberg A, Olafsson I, Eyjolfsson GI, Jørgensen T, Wang J, Hansen T, Thorsteinsdottir U, Stefánsson K, Pedersen O. Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets. *PLoS Genet* 2013; **9**: e1003530 [PMID: 23754956 DOI: 10.1371/journal.pgen.1003530]

17 **Mondul AM**, Yu K, Wheeler W, Zhang H, Weinstein SJ, Major JM, Cornelis MC, Männistö S, Hazra A, Hsing AW, Jacobs KB, Eliassen H, Tanaka T, Reding DJ, Hendrickson S, Ferrucci L, Virtamo J, Hunter DJ, Chanock SJ, Kraft P, Albanes D. Genome-wide association study of circulating retinol levels. *Hum Mol Genet* 2011; **20**: 4724-4731 [PMID: 21878437 DOI: 10.1093/hmg/ddr387]

18 **Dashti HS**, Shea MK, Smith CE, Tanaka T, Hruby A, Richardson K, Wang TJ, Nalls MA, Guo X, Liu Y, Yao J, Li D, Johnson WC, Benjamin EJ, Kritchevsky SB, Siscovick DS, Ordovás JM, Booth SL. Meta-analysis of genome-wide association studies for circulating phylloquinone concentrations. *Am J Clin Nutr* 2014; **100**: 1462-1469 [PMID: 25411281 DOI: 10.3945/ajcn.114.093146]

19 **Locke AE**, Steinberg KM, Chiang CWK, Service SK, Havulinna AS, Stell L, Pirinen M, Abel HJ, Chiang CC, Fulton RS, Jackson AU, Kang CJ, Kanchi KL, Koboldt DC, Larson DE, Nelson J, Nicholas TJ, Pietilä A, Ramensky V, Ray D, Scott LJ, Stringham HM, Vangipurapu J, Welch R, Yajnik P, Yin X, Eriksson JG, Ala-Korpela M, Järvelin MR, Männikkö M, Laivuori H; FinnGen Project, Dutcher SK, Stitziel NO, Wilson RK, Hall IM, Sabatti C, Palotie A, Salomaa V, Laakso M, Ripatti S, Boehnke M, Freimer NB. Exome sequencing of Finnish isolates enhances rare-variant association power. *Nature* 2019; **572**: 323-328 [PMID: 31367044 DOI: 10.1038/s41586-019-1457-z]

20 **Dupuis J**, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Mägi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JR, Egan JM, Lajunen T, Grarup N, Sparsø T, Doney A, Voight BF, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proença C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarroll SA, Payne F, Roccasecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben-Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Böttcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen YD, Chines P, Clarke R, Coin LJ, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day IN, de Geus EJ, Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves CJ, Grundy S, Gwilliam R, Gyllensten U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen AL, Hassanali N, Hayward C, Heath SC, Hercberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PR, Jørgensen T, Jula A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martínez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orrù M, Pakyz R, Palmer CN, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AF, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott LJ, Seedorf U, Sharp SJ, Shields B, Sigurethsson G, Sijbrands EJ, Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, Syvänen AC, Tanaka T, Thorand B, Tichet J,

Tönjes A, Tuomi T, Uitterlinden AG, van Dijk KW, van Hoek M, Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemsen G, Witteman JC, Yarnell JW, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium, Borecki IB, Loos RJ, Meneton P, Magnusson PK, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Ríos M, Morris AD, Lind L, Palmer LJ, Hu FB, Franks PW, Ebrahim S, Marmot M, Kao WH, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, Pramstaller PP, Wichmann HE, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell H, Wilson JF; Anders Hamsten on behalf of Procardis Consortium; MAGIC investigators, Bergman RN, Buchanan TA, Collins FS, Mohlke KL, Tuomilehto J, Valle TT, Altshuler D, Rotter JI, Siscovick DS, Penninx BW, Boomsma DI, Deloukas P, Spector TD, Frayling TM, Ferrucci L, Kong A, Thorsteinsdottir U, Stefansson K, van Duijn CM, Aulchenko YS, Cao A, Scuteri A, Schlessinger D, Uda M, Ruokonen A, Jarvelin MR, Waterworth DM, Vollenweider P, Peltonen L, Mooser V, Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L, Boehnke M, McCarthy MI, Florez JC, Barroso I. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet* 2010; **42**: 105-116 [PMID: 20081858 DOI: 10.1038/ng.520]

21 **Park S**, Lee S, Kim Y, Lee Y, Kang MW, Kim K, Kim YC, Han SS, Lee H, Lee JP, Joo KW, Lim CS, Kim YS, Kim DK. Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study. *medRxiv* 2020 [DOI: 10.1101/2020.07.31.20166207]

22 **Holmes MV**, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. *Nat Rev Cardiol* 2017; **14**: 577-590 [PMID: 28569269 DOI: 10.1038/nrcardio.2017.78]

23 **Bowden J**, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* 2016; **40**: 304-314 [PMID: 27061298 DOI: 10.1002/gepi.21965]

24 **Burgess S**, Thompson SG. Erratum to: Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol* 2017; **32**: 391-392 [PMID: 28664250 DOI: 10.1007/s10654-017-0276-5]

25 **Fu Y**, Xu F, Jiang L, Miao Z, Liang X, Yang J, Larsson SC, Zheng JS. Circulating vitamin C concentration and risk of cancers: a Mendelian randomization study. *BMC Med* 2021; **19**: 171 [PMID: 34325683 DOI: 10.1186/s12916-021-02041-1]

26 **Verbanck M**, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet* 2018; **50**: 693-698 [PMID: 29686387 DOI: 10.1038/s41588-018-0099-7]

27 **Chen L**, Sun X, Wang Z, Lu Y, Chen M, He Y, Xu H, Zheng L. The impact of plasma vitamin C levels on the risk of cardiovascular diseases and Alzheimer's disease: A Mendelian randomization study. *Clin Nutr* 2021; **40**: 5327-5334 [PMID: 34537655 DOI: 10.1016/j.clnu.2021.08.020]

28 **Panidis D**, Balaris C, Farmakiotis D, Rousso D, Kourtis A, Balaris V, Katsikis I, Zournatzi V, Diamanti-Kandarakis E. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. *Clin Chem* 2005; **51**: 1691-1697 [PMID: 16037412 DOI: 10.1373/clinchem.2005.052761]

29 **Hahn S**, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, Kimmig R, Mann K, Janssen OE. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. *Exp Clin Endocrinol Diabetes* 2006; **114**: 577-583 [PMID: 17177140 DOI: 10.1055/s-2006-948308]

30 **Tefagh G**, Payab M, Qorbani M, Sharifi F, Sharifi Y, Ebrahimnegad Shirvani MS, Pourghazi F, Atlasi R, Shadman Z, Rezaei N, Mohammadi-Vajari E, Larijani B, Ebrahimpur M. Effect of vitamin E supplementation on cardiometabolic risk factors, inflammatory and oxidative markers and hormonal functions in PCOS (polycystic ovary syndrome): a systematic review and meta-analysis. *Sci Rep* 2022; **12**: 5770 [PMID: 35388031 DOI: 10.1038/s41598-022-09082-3]

31 **Yalle-Vásquez S**, Osco-Rosales K, Nieto-Gutierrez W, Benites-Zapata V, Pérez-López FR, Alarcon-Ruiz CA. Vitamin E supplementation improves testosterone, glucose- and lipid-related metabolism in women with polycystic ovary syndrome: a meta-analysis of randomized clinical trials. *Gynecol Endocrinol* 2022; **38**: 548-557 [PMID: 35612360 DOI: 10.1080/09513590.2022.2079629]

32 **Lee GY**, Han SN. The Role of Vitamin E in Immunity. *Nutrients* 2018; **10** [PMID: 30388871 DOI: 10.3390/nu10111614]

33 **Palamanda JR**, Kehrer JP. Involvement of vitamin E and protein thiols in the inhibition of microsomal lipid peroxidation by glutathione. *Lipids* 1993; **28**: 427-431 [PMID: 8316051 DOI: 10.1007/bf02535941]

34 **Izadi A**, Ebrahimi S, Shirazi S, Taghizadeh S, Parizad M, Farzadi L, Gargari BP. Hormonal and Metabolic Effects of Coenzyme Q10 and/or Vitamin E in Patients With Polycystic Ovary Syndrome. *J Clin Endocrinol Metab* 2019; **104**: 319-327 [PMID: 30202998 DOI: 10.1210/jc.2018-01221]

35 **Zhang J**, Xing C, Zhao H, He B. The effectiveness of coenzyme Q10, vitamin E, inositols, and vitamin D in improving the endocrine and metabolic profiles in women with polycystic ovary syndrome: a network Meta-analysis. *Gynecol Endocrinol* 2021; **37**: 1063-1071 [PMID: 33988478 DOI: 10.1080/09513590.2021.1926975]

36 **Kennedy DO**. B Vitamins and the Brain: Mechanisms, Dose and Efficacy--A Review. *Nutrients* 2016; **8**: 68 [PMID: 26828517 DOI: 10.3390/nu8020068]

37 **Kilicdag EB**, Bagis T, Tarim E, Aslan E, Erkanli S, Simsek E, Haydardedeoglu B, Kuscu E. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. *Hum Reprod* 2005; **20**: 1521-1528 [PMID: 15790610 DOI: 10.1093/humrep/deh825]

38 **Thomas-Valdés S**, Tostes MDGV, Anunciação PC, da Silva BP, Sant'Ana HMP. Association between vitamin deficiency and metabolic disorders related to obesity. *Crit Rev Food Sci Nutr* 2017; **57**: 3332-3343 [PMID: 26745150 DOI: 10.1080/10408398.2015.1117413]

39 **Yuan S**, Mason AM, Carter P, Burgess S, Larsson SC. Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. *BMC Med* 2021; **19**: 97 [PMID: 33888102 DOI: 10.1186/s12916-021-01977-8]

Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com